Cara Therapeutics | CARA

Stock Price
3.26
Daily Change
0%
Yearly
-60.48%
Q2 Forecast
3.00
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Chugai Pharma 3,965.00 100.00 2.59% 9.89%
Acadia Pharmaceuticals 24.94 -0.16 -0.62% 45.90%
Cara Therapeutics 3.26 0 0% -60.48%
Depomed 5.97 -0.06 -0.91% 91.80%
Endo International 0.06 0.01 9.09% -82.44%
Halozyme Therapeutics 34.02 -0.14 -0.41% -22.31%
Horizon Pharma 99.52 0.10 0.10% 16.50%
J&J 160.10 -0.16 -0.10% -7.22%
Neurocrine Biosciences 93.51 -0.52 -0.55% -0.85%
Pacira 36.62 -0.39 -1.05% -34.34%
Pfizer 39.05 -0.04 -0.10% -21.85%
Cassava Sciences Inc. 24.11 -0.37 -1.51% -12.29%
RedHill Biopharma 1.87 -0.06 -3.00% 106.43%
Revance Therapeutics 30.85 -0.28 -0.90% 156.87%
Supernus Pharmaceuticals 35.10 -0.49 -1.38% 29.28%
Vanda Pharmaceuticals 6.50 0 0% -33.47%

Indexes Price Day Year
USND 13256 17.65 0.13% 16.90%
US2000 1867 -13.99 -0.74% 3.69%

Cara Therapeutics

Cara Therapeutics traded at $3.26 this Friday June 9th, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics lost 21.45 percent. Over the last 12 months, its price fell by 60.48 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 3.00 by the end of this quarter and at 2.75 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.